Sotyktu (generic name: deucravacitinib) is an oral medication prescribed for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Deucravacitinib is a selective inhibitor of tyrosine kinase 2 (TYK2), an enzyme that plays a pivotal role in the inflammatory pathways associated with psoriasis. By inhibiting TYK2, deucravacitinib disrupts the signaling of cytokines such as interleukin-12 (IL-12) and interleukin-23 (IL-23), which are involved in the inflammatory process of psoriasis. This targeted inhibition helps reduce the overactive immune response characteristic of the condition.
Deucravacitinib belongs to the class of medications known as TYK2 inhibitors, which are a subset of the broader category of Janus kinase (JAK) inhibitors. However, deucravacitinib’s selective inhibition of TYK2 differentiates it from other JAK inhibitors, offering a distinct safety and efficacy profile.
Sotyktu represents a significant advancement in the treatment of moderate to severe plaque psoriasis by selectively targeting TYK2. Its oral administration offers convenience, and its mechanism provides a targeted approach to managing the inflammatory processes underlying psoriasis.Â
Dosage and Administration
The standard dosage for Sotyktu is 6 mg taken orally once daily. Patients can take the tablet with or without food, according to their preference. It is important to swallow the tablet whole; patients should not crush, cut, or chew it.
If a patient misses a dose of Sotyktu, they should take the missed dose as soon as they remember. However, if it is almost time for the next scheduled dose, they should skip the missed dose and resume their regular dosing schedule. Patients should not double-dose to make up for a missed dose.
Storage
Sotyktu should be stored at room temperature, between 68°F to 77°F (20°C to 25°C). It is important to keep the medication in its original container, tightly closed, and away from moisture and heat. Patients should also ensure that Sotyktu is kept out of reach of children.
Common Questions About Sotyktu
How does deucravacitinib work?
Deucravacitinib selectively inhibits the tyrosine kinase 2 (TYK2) enzyme, which plays a role in the inflammatory pathways associated with psoriasis. By inhibiting TYK2, it helps reduce the overactive immune response characteristic of the condition.
What is plaque psoriasis?
Plaque psoriasis is a chronic autoimmune condition characterized by the rapid buildup of skin cells, leading to the formation of scales and red patches that can be itchy and sometimes painful.
How do TYK2 inhibitors differ from other psoriasis treatments?
TYK2 inhibitors, like Sotyktu, offer a targeted approach by selectively inhibiting the TYK2 enzyme involved in the inflammatory process of psoriasis, potentially offering a distinct safety and efficacy profile compared to other treatments.
This text is for informational purposes only. Please consult a doctor or pharmacist before using any medication.Â
Read the information leaflet that comes with the medication.
Most people who use Sotyktu do not experience any adverse side effects. Doctors prescribe this medication because they assess the benefits of such treatment outweigh any likely unwanted effects.
Some of the side effects that have been reported include:
- Upper respiratory tract infections
- Herpes simplex infections
- Folliculitis
- Acne
- Headache
- Diarrhea and nausea
- Hypertension
- Back pain and joint pain
- Fatigue
Not all side effects are listed here. If these or other unlisted symptoms persist or worsen, consult a healthcare provider or pharmacist.
Sotyktu is approved for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Plaque Psoriasis
Plaque psoriasis is a chronic autoimmune condition characterized by the rapid buildup of skin cells, leading to the formation of scales and red patches that can be itchy and sometimes painful. Common symptoms include:
- Red patches of skin covered with thick, silvery scales
- Dry, cracked skin that may bleed
- Itching, burning, or soreness
- Thickened or ridged nails
- Swollen and stiff joints
Sotyktu works by inhibiting TYK2, thereby reducing the inflammatory activity that leads to these symptoms.